Drugs / ES101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04009460 | Jun 2019 → Apr 2022 | cancer | Elpiscience Biopharma, Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04841538 | Jul 2021 → Dec 2023 | non-small cell lung carcinoma, small cell lung carcinoma | Elpiscience Biopharma, Ltd. | Withdrawn | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-02-22 | Elpiscience Biopharma, Ltd. | Regulatory Elpiscience Announces Clinical Trial Approval of ES101 in China elpiscience.com ↗
Elpiscience Biopharma, Ltd. announced today that the bispecific antibody ES101 has been approved by the Center for Drug Evaluation (CDE) for clinical trials in China. |
| 2018-10-20 | Elpiscience Biopharma, Ltd. | Regulatory Elpiscience Announces Filing of IND for ES101 elpiscience.com ↗
Elpiscience announced today that it has submitted an Investigational New Drug (IND) application to the Center of Drug Evaluation (CDE) in Beijing to support the initiation of a Phase I clinical trial of ES101 in China. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-06-28 | Elpiscience Biopharma, Ltd. | ES101: First Patient Dosing in Phase I Clinical Trials elpiscience.com ↗ |
| 2019-02-22 | Elpiscience Biopharma, Ltd. | Elpiscience Announces Clinical Trial Approval of ES101 in China elpiscience.com ↗ |
| 2018-10-20 | Elpiscience Biopharma, Ltd. | Elpiscience Announces Filing of IND for ES101 elpiscience.com ↗ |
| 2018-03-01 | Elpiscience Biopharma, Ltd. | Elpiscience and Inhibrx Announce an Exclusive Collaboration and License Agreement of INBRX-105 (ES101) in Greater China elpiscience.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ES101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04841538 ↗ |
| Known as | INBRX-105 | “ES101 (INBRX-105; PDL1x4-1BB antibody) is a recombinant humanized bispecific IgG1 antibody targeting human PD-L1 and 4-1BB.” NCT04009460 ↗ |
| Route | Intravenous | “ES101 is administered via intravenous infusion” NCT04009460 ↗ |